Sector Gamma AS Grows Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Sector Gamma AS boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 14.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 217,348 shares of the biotechnology company's stock after buying an additional 27,000 shares during the period. BioMarin Pharmaceutical accounts for approximately 4.9% of Sector Gamma AS's investment portfolio, making the stock its 7th largest holding. Sector Gamma AS owned 0.11% of BioMarin Pharmaceutical worth $14,286,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Oregon Public Employees Retirement Fund lifted its stake in BioMarin Pharmaceutical by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock valued at $2,546,000 after buying an additional 164 shares in the last quarter. Fifth Third Bancorp raised its position in BioMarin Pharmaceutical by 13.9% during the fourth quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock valued at $89,000 after buying an additional 165 shares during the period. Advisors Asset Management Inc. lifted its stake in BioMarin Pharmaceutical by 1.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company's stock worth $805,000 after acquiring an additional 180 shares in the last quarter. TD Private Client Wealth LLC boosted its position in BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares during the period. Finally, First Hawaiian Bank grew its stake in BioMarin Pharmaceutical by 1.4% during the 4th quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock valued at $966,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

Remove Ads

BioMarin Pharmaceutical Trading Down 0.4 %

BMRN stock traded down $0.30 during midday trading on Tuesday, reaching $71.70. The stock had a trading volume of 36,321 shares, compared to its average volume of 1,786,953. The firm has a market cap of $13.68 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 0.61 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a twelve month low of $60.63 and a twelve month high of $94.85. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The business has a fifty day simple moving average of $66.68 and a two-hundred day simple moving average of $67.87.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. As a group, research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Insider Transactions at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,295 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total transaction of $92,618.40. Following the completion of the transaction, the chief accounting officer now directly owns 16,955 shares in the company, valued at approximately $1,212,621.60. The trade was a 7.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.85% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BMRN has been the topic of a number of research analyst reports. StockNews.com raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 18th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. UBS Group lifted their price target on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Bank of America raised their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Finally, Scotiabank raised their price target on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a report on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $94.00.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.